Month: May 2022

Landsbankinn’s net profit in the first three months of 2022 was ISK 3.2 billion.  Return on equity (ROE) was 4.7%.  Net fee and commission income increased by 28.5% YoY, mainly from growing activity in asset management and capital markets.  Net interest income grew by 19%, mainly driven by a larger balance sheet and better returns on liquid assets. Market share in the retail market measured 38.7% at the end of the quarter, slightly higher than in the same quarter last year.  The cost/income ratio was 54.9% and costs remain stable. Operating expenses as a ratio of average total assets were 1.4%. Growth in mortgage lending has declined while lending to corporates increased by ISK 20.7 billion, not having regard for exchange rate impact. Around 90% of new housing mortgages in the first quarter were non-indexed and 58% of the mortgages carry...

Board Declares Quarterly Dividend of $0.25 per Share PHILADELPHIA and NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — In a news release issued earlier today under the same headline by Cohen & Company Inc. (NYSE American: COHN), please be advised that several figures have been updated. In the first bullet under Financial Highlights, adjusted pre-tax loss of “$5.8 million” has changed to “$18.6 million” and “$4.14 per diluted share” has changed to “$3.35 per diluted share.” The “Summary Operating Results” and “Consolidated Statements of Operations” tables have been revised. Complete corrected text follows: Cohen & Company Inc. (NYSE American: COHN), a financial services firm specializing in fixed income and SPAC markets, today reported financial results for...

May 5th2022 Q1 2022 Interim Report and Investor Conference Call Announcement Welltec® will disclose its Q1 2022 Interim Report and will discuss the results during an investor conference call to be held Thursday, May 12th, 2022, at 5 pm CEST. The conference call will be available only to current and prospective bond holders, broker dealers, and securities analysts, and can be accessed by dialing in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Mads Brixtofte Rasmussen mbrasmussen@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The Q1 2022 Interim Report will be made available in the “Investor Room” on Welltec’s...

GROSSE POINTE FARMS, Mich., May 05, 2022 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) reported today that net revenue increased 12.0% to $25.0 million for the quarter ended March 31, 2022 compared to $22.3 million for the same period last year. Station operating expense increased 8.7% for the quarter to $20.6 million compared to the same period last year. For the quarter station operating income increased 17.8% to $5.6 million and operating income was $1.7 million compared to $883 thousand for the quarter last year. Free cash flow was $1.9 million for the quarter compared to $1.8 million for the same period last year. Net income was $1.2 million for the quarter compared to $758 thousand for the first quarter last year. Diluted earnings per share were $0.20 in the first quarter of 2022. The Company paid a quarterly...

– $209.7 Million Cash and Cash Equivalents at March 31, 2022 – – Over 120 Patients Now Enrolled in Phase 3 Program – AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candidate for the proposed treatment of Alzheimer’s disease. Net loss was $17.5 million, or $0.44 per share, compared to a net loss of $3.5 million, or $0.09 per share, for the same period in 2021. Net cash used in operations was $23.5 million during the first quarter of 2022, including over $10 million of contractual pre-payments....

Highlights:Revenue of $164.9 million for the quarter ended March 31, 2022Excluding revenue from divested businesses, revenue increased 11% year-over-yearDiluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectively Ended the quarter with $339.2 million in cash, cash equivalents and investments New partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selection TestSALT LAKE CITY, May 05, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its first quarter 2022. The company also reiterated long-term and 2022 financial guidance and provided an update on business performance, recent product...